Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.72 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7989616 | 0.98 | HTT (0.70) | HTTFGFR1KDM4EALDH1A1RAB9A | |
| SCHEMBL3419279 | 0.90 | HTT (0.88) | HTTFGFR1KDM4EALDH1A1RAB9A | |
| SCHEMBL30402227 | 0.90 | HTT (0.88) | HTTFGFR1KDM4EALDH1A1RAB9A | |
| SCHEMBL2531256 | 0.85 | HTT (0.78) | HTTFGFR1KDM4EALDH1A1RAB9A | |
| Benzene SCHEMBL14876970 | 0.84 | HTT (1.00) | HTTFGFR1 | |
| SCHEMBL157265 | 0.84 | HTT (1.00) | HTTFGFR1 | |
| SCHEMBL6048284 | 0.84 | HTT (0.65) | HTTFGFR1 | |
| SCHEMBL5246440 | 0.83 | HTT (0.75) | HTTFGFR1KDM4EALDH1A1RAB9A | |
| SCHEMBL4891428 | 0.82 | HTT (0.96) | HTTFGFR1 | |
| SCHEMBL467858 | 0.82 | HTT (0.96) | HTTFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3424924-B1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL SHANGHAI CO LTD (CN) | 2023-05-24 | — | — | EP | claimed |
| CN-114133380-B | Purpurin derivative electrochromism and electroluminescent photochromic material, and preparation method and application thereof | 华南理工大学 | 2022-12-16 | — | — | CN | claimed |
| CN-114133380-A | Purpurin derivative electrochromism and electroluminescent photochromic material, and preparation method and application thereof | 华南理工大学 | 2022-03-04 | — | — | CN | claimed |
| US-10647680-B2 | Urea compound, preparation method therefor and medical use thereof | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2020-05-12 | — | — | US | claimed |
| US-20190047964-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-02-14 | — | — | US | claimed |
| EP-3424924-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Ancureall Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2019-01-09 | — | — | EP | claimed |
| CN-109071523-A | Urea compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2018-12-21 | — | — | CN | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-3424924-B1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL SHANGHAI CO LTD (CN) | 2023-05-24 | — | — | EP | disclosed |
| EP-3424924-B1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL SHANGHAI CO LTD (CN) | 2023-05-24 | — | — | EP | disclosed |
| CN-114133380-B | Purpurin derivative electrochromism and electroluminescent photochromic material, and preparation method and application thereof | 华南理工大学 | 2022-12-16 | — | — | CN | disclosed |
| CN-109071523-B | Urea compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-20110046105-A1 | Heterocycle-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising them and use thereof | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | US | disclosed |
| WO-2010012745-A2 | BENZIMIDAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | WO | disclosed |
| EP-0946508-B1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-09-23 | — | — | EP | disclosed |
| US-6548512-B1 | Pyrazole derivatives such as 1-(3-amidinophenyl)-3-methyl-2-((5-(2'-aminosulfonylphenyl-1-yl)pyrimidin-2 -yl)aminocarbonyl)pyrazole; treating thromboembolic disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-6020357-A | CARDIOVASCULAR DISORDERS; ANTCOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0946508-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028269-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047964-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | FLT3, WEE1, SLC14A1 | HTT 3467/4885FGFR1 294/4885KDM4E 2072/4885 |
| US-10647680-B2 | Urea compound, preparation method therefor and medical use thereof | FLT3, WEE1, SLC14A1 | HTT 3467/4885FGFR1 294/4885KDM4E 2072/4885 |
| US-20110046105-A1 | Heterocycle-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising them and use thereof | GIPR, DDC, PGC | HTT 1571/4885FGFR1 1069/4885KDM4E 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.